Medytox submits BLA for non-animal-derived liquid BTX formulation in US

By Korea BioMedical Review

December 28, 2023

Medytox said it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for MT10109L, a non-animal-derived liquid botulinum toxin (BTX) formulation indicated for improving moderate to severe frown lines and crow’s feet.

To read the full press release, click here.